PT-141
Bremelanotide
Each vial contains 10 mg of PT-141.
PT-141, also called bremelanotide, is a synthetic melanocortin receptor agonist and a metabolite of Melanotan II. Which receptors it acts at, what the trials examined, and what is approved and what is not are set out under How it works below.
- Lyophilized powder, requires reconstitution
Price
$55.00 CAD
In stock
Produced & shipped in Canada
Specification
- CAS number
- 189691-06-3
- Molecular formula
- C50H68N14O10
- Molecular weight
- 1,025.16 g/mol
- Purity
- ≥ 99.0% by RP-HPLC
- Form
- Lyophilized powder
- Third-party assay
- Purity, fill and endotoxin
- Origin
- Canada
- Storage
- -20 °C, protected from light
- Lot
- NVE-2442-A
How it works
Where it acts is the whole of the distinction this literature draws. Melanocortin receptors in the central nervous system are the site the papers and the approved label both name, rather than the penile vasculature the PDE5 drugs were characterised against.
Melanocortin receptors (MC3/MC4)
Central, where it acts
A melanocortin-3 and melanocortin-4 receptor agonist acting in the central nervous system. That central site is what the papers characterise, and what the approved label of the finished drug names as the mechanism.
PDE5 inhibitors
A different class, peripheral
A different class with a different site, and the comparison readers arrive with. Nothing in those papers is a finding about a melanocortin agonist, and nothing in these is a finding about them — the two literatures do not transfer either way.
Vyleesi (bremelanotide)
The approved medicine, not this vial
The FDA approved Vyleesi in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. That indication belongs to the finished, inspected, prescribed product. It is not an indication for research material sold here.
Work in men
Investigated, not an approved indication
Published studies have enrolled men with erectile dysfunction. The FDA label of Vyleesi states it is not indicated in men; no approved male indication exists for this molecule, and none exists for this vial.
Where the evidence stands
The RECONNECT phase 3 trials in premenopausal women with hypoactive sexual desire disorder were published and reviewed by the FDA. Vyleesi (bremelanotide) was approved in 2019 for that indication. Material on this page is research material, not that medicine. Work in men remains without an approved indication. An earlier intranasal programme was abandoned after blood-pressure signals and is part of the same record.
Laboratory results
Opened as the laboratory issued them, unedited. Every certificate we publish
Research use only
Supplied as a laboratory research chemical. Not a drug, food or cosmetic, and not for human or veterinary use. No application guidance is provided or implied.
